The Effects of Psilocybin on Social Connectedness
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age21-65
SponsorYale University
About this trial
The study is a randomized, double-blind, placebo-controlled, expectancy-controlled, mechanistic trial. This study looks to explore whether a single dose of psilocybin (25mg) reduces amygdala reactivity to negative socioemotional stimuli during the Facial Emotion Recognition Task (FERT) compared to a placebo in adults who feel lonely or those with unresolved grief symptoms.
Eligibility criteria
Qualifiers
Medically healthy
Ability to provide consent
High loneliness defined by the UCLA-3 Loneliness Scale
Willingness to comply with all study procedures and availability for the duration of the study
Disqualifiers
Any unstable medical condition, psychiatric disorder, or circumstance that, in the opinion of the investigator, could compromise participant safety, interfere with study participation, or hinder the participant's ability to comply with study procedures and requirements
Positive pregnancy test or women who are breastfeeding
Any contraindication to MRI such as a pacemaker or metal implants
Trial design
Treatments tested in this trial
- Psilocybin
- Placebo
Treatment groups
51 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov